BG101278A - Hard systems designed for controlled release of moleculesintroduced in them and methods for their preparation - Google Patents

Hard systems designed for controlled release of moleculesintroduced in them and methods for their preparation

Info

Publication number
BG101278A
BG101278A BG101278A BG10127897A BG101278A BG 101278 A BG101278 A BG 101278A BG 101278 A BG101278 A BG 101278A BG 10127897 A BG10127897 A BG 10127897A BG 101278 A BG101278 A BG 101278A
Authority
BG
Bulgaria
Prior art keywords
methods
moleculesintroduced
preparation
systems
controlled release
Prior art date
Application number
BG101278A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruce Roser
Camilo Colaco
Mohamed Jerrow
Julian Blair
Jaap Kampinga
James Wardell
John Duffy
Original Assignee
Quadrant Holdings Cambridge Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG101278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9415810A external-priority patent/GB9415810D0/en
Priority claimed from US08/349,029 external-priority patent/US6290991B1/en
Application filed by Quadrant Holdings Cambridge Limited filed Critical Quadrant Holdings Cambridge Limited
Publication of BG101278A publication Critical patent/BG101278A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Lubricants (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BG101278A 1994-08-04 1997-02-28 Hard systems designed for controlled release of moleculesintroduced in them and methods for their preparation BG101278A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415810A GB9415810D0 (en) 1994-08-04 1994-08-04 Composition
US08/349,029 US6290991B1 (en) 1994-12-02 1994-12-02 Solid dose delivery vehicle and methods of making same
PCT/GB1995/001861 WO1996003978A1 (en) 1994-08-04 1995-08-04 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Publications (1)

Publication Number Publication Date
BG101278A true BG101278A (en) 1997-12-30

Family

ID=26305403

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101278A BG101278A (en) 1994-08-04 1997-02-28 Hard systems designed for controlled release of moleculesintroduced in them and methods for their preparation

Country Status (20)

Country Link
EP (4) EP1516615A3 (no)
JP (2) JPH10503769A (no)
CN (1) CN1152670C (no)
AT (1) ATE252373T1 (no)
BG (1) BG101278A (no)
CA (1) CA2197982C (no)
CZ (1) CZ297431B6 (no)
DE (1) DE69531992T2 (no)
DK (1) DK0773781T3 (no)
EE (1) EE03593B1 (no)
ES (1) ES2208687T3 (no)
FI (1) FI970867A (no)
HU (1) HUT77777A (no)
MX (1) MX9701394A (no)
NO (1) NO326966B1 (no)
NZ (1) NZ290896A (no)
PL (1) PL184068B1 (no)
PT (1) PT773781E (no)
SK (1) SK283026B6 (no)
WO (1) WO1996003978A1 (no)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
WO1996008979A1 (en) 1994-09-22 1996-03-28 Quadrant Holdings Cambridge Limited Compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US6517860B1 (en) * 1996-12-31 2003-02-11 Quadrant Holdings Cambridge, Ltd. Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery
GB9705588D0 (en) 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
JP2002510316A (ja) * 1997-07-03 2002-04-02 クアドラント ホールディングス ケンブリッジ リミテッド 修飾グリコシド、これを含む組成物およびその使用方法
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
CA2317411C (en) * 1998-01-30 2005-06-28 Scios Inc. Controlled release delivery of peptide or protein
US6455096B1 (en) 1998-04-28 2002-09-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Hard candy with a relatively-high moisture and hardness, and process of the same
AU5751799A (en) * 1998-09-09 2000-03-27 Quadrant Holdings Cambridge Limited Filamentous amorphous carbohydrate compositions and therapeutic delivery vehicles comprising them
ATE244558T1 (de) 1999-04-16 2003-07-15 Novo Nordisk As Trockene formbare arzneistoffformulierung
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
JP3419729B2 (ja) * 2000-03-16 2003-06-23 株式会社ファンケル 錠剤およびその製造方法
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
EP1452171B1 (en) * 2000-10-13 2009-12-02 Cambridge Biostability Limited Pharmaceutical liquid suspensions
RU2282468C2 (ru) 2000-10-26 2006-08-27 Алза Корпорейшн Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием
MXPA03009603A (es) * 2001-04-20 2004-12-06 Johnson & Johnson Arreglo de microproyeccion que tiene un agente benefico que contiene un recubrimiento.
GB0124710D0 (en) * 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
ATE401058T1 (de) 2001-11-01 2008-08-15 Nektar Therapeutics Sprühtrocknungsverfahren
DE10157124A1 (de) * 2001-11-21 2003-05-28 Lohmann Therapie Syst Lts Mikrofaserhaltige Vorrichtung zur kontrollierten Freisetzung von Stoffen
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
EP1458360B1 (en) 2001-12-19 2011-05-11 Novartis AG Pulmonary delivery of aminoglycosides
ATE357219T1 (de) * 2002-01-25 2007-04-15 Glaxo Group Ltd Darreichungsformen für dns
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0210771D0 (en) * 2002-05-10 2002-06-19 Univ London Pharmacy Derivatised particulate inhalation carriers
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
ES2437565T3 (es) 2003-06-30 2014-01-13 Alza Corporation Formulaciones para microproyecciones revestidas que contienen contraiones no volátiles
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
GB0327727D0 (en) * 2003-11-28 2003-12-31 Quadrant Drug Delivery Ltd Viral microparticles
ES2313350T3 (es) 2004-05-12 2009-03-01 Baxter International Inc. Microesferas de acido nucleico, produccion y suministro de las mismas.
DK1758558T3 (da) 2004-05-12 2014-01-20 Baxter Int Oligonukleotidholdige mikrokugler samt deres anvendelse til fremstilling af et medikament til behandling af diabetes type 1
JP4547994B2 (ja) 2004-06-02 2010-09-22 救急薬品工業株式会社 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
US20070009564A1 (en) 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
CA2624503A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
JP2009522288A (ja) 2005-12-28 2009-06-11 アルザ コーポレイション 安定な治療剤形
EP1832281A1 (en) 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US7887521B2 (en) 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US7871399B2 (en) 2006-05-17 2011-01-18 Alcon Research, Ltd. Disposable ophthalmic injection device
US20070270750A1 (en) 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US7674243B2 (en) 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US7811252B2 (en) 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US7862540B2 (en) 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US9022970B2 (en) 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
US20080281292A1 (en) 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
PT2101731T (pt) * 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
US7740619B2 (en) 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
US7629768B2 (en) 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
JP6062851B2 (ja) * 2010-04-30 2017-01-18 アロヴェイト・エルエルシー 口腔粘膜を介してアレルギーを減感作するための方法、物品及びキット
EP2397484A1 (en) * 2010-06-11 2011-12-21 Immunovo B.V. Trisaccharide derivates, and their use as adjuvants
CN104023743B (zh) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
KR101574760B1 (ko) 2013-11-13 2015-12-04 주식회사 엘지생활건강 흡수속도를 개선한 마이크로니들 시스템
WO2015093452A1 (ja) 2013-12-16 2015-06-25 武田薬品工業株式会社 マイクロニードル
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
MX2018002533A (es) 2015-09-29 2018-06-27 Kimberly Clark Co Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
KR102114993B1 (ko) * 2015-10-15 2020-05-25 주식회사 파이안에스테틱스 폴리펩타이드 및/또는 세포 배양 여액을 함유하는 수용성 스크럽 입자를 포함하는 화장제 조성물
GB2545880A (en) 2015-10-20 2017-07-05 Glide Pharmaceutical Tech Ltd Solid formulation
BR112018017173A2 (pt) 2016-02-23 2019-01-02 Univ Colorado Regents composições e métodos para a produção e uso de formulações imunogênicas termoestáveis com compatibilidade aumentada de uso como vacinas contra um ou mais patógenos
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
WO2023077447A1 (zh) * 2021-11-05 2023-05-11 中国科学院过程工程研究所 环肽玻璃及含有环肽的药物组合物玻璃

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1080265B (de) * 1958-09-30 1960-04-21 Bayer Ag Verfahren zur Herstellung von oral anzuwendenden Arzneimittel-zubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
DE3682047D1 (de) 1985-07-09 1991-11-21 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01288023A (ja) * 1988-05-16 1989-11-20 Nec Corp ミリ波構内無線通信方式
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
WO1990011756A1 (en) * 1989-04-12 1990-10-18 Aberdeen University Slow release vitreous systems
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009390D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Pharmaceutical compositions
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
DE69212497T2 (de) * 1991-12-05 1996-12-12 Mallinckrodt Veterinary Inc Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
DK42093D0 (da) * 1993-04-07 1993-04-07 Bukh Meditec Administrationsmetode
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use

Also Published As

Publication number Publication date
EP0773781B1 (en) 2003-10-22
NO326966B1 (no) 2009-03-23
DE69531992D1 (de) 2003-11-27
EP0773781A1 (en) 1997-05-21
SK283026B6 (sk) 2003-02-04
EP1138319A3 (en) 2003-03-19
FI970867A0 (fi) 1997-02-28
MX9701394A (es) 1998-03-31
PL318898A1 (en) 1997-07-21
PL184068B1 (pl) 2002-08-30
FI970867A (fi) 1997-04-08
DK0773781T3 (da) 2004-02-16
ATE252373T1 (de) 2003-11-15
CN1152670C (zh) 2004-06-09
NZ290896A (en) 1997-04-24
SK27797A3 (en) 1997-08-06
EE03593B1 (et) 2002-02-15
ES2208687T3 (es) 2004-06-16
EP1138337A2 (en) 2001-10-04
EP1138337A3 (en) 2003-03-26
CA2197982A1 (en) 1996-02-15
NO971688L (no) 1997-04-11
JP2006056898A (ja) 2006-03-02
EE9700062A (et) 1997-08-15
EP1516615A2 (en) 2005-03-23
WO1996003978A1 (en) 1996-02-15
CZ297431B6 (cs) 2006-12-13
CA2197982C (en) 2010-03-23
HUT77777A (hu) 1998-08-28
NO971688D0 (no) 1997-04-11
CZ47697A3 (en) 1997-08-13
EP1138319A2 (en) 2001-10-04
PT773781E (pt) 2004-03-31
CN1204959A (zh) 1999-01-13
JPH10503769A (ja) 1998-04-07
EP1516615A3 (en) 2007-10-31
AU3185195A (en) 1996-03-04
DE69531992T2 (de) 2004-07-22
AU688557B2 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
BG101278A (en) Hard systems designed for controlled release of moleculesintroduced in them and methods for their preparation
GB2221157B (en) Intravenous pharmaceutical composition comprising cyclosporin and process for preparing the same
GEP20074095B (en) Analogs of human insulin modified at position 29 of the b chain thereof
SI0825178T1 (en) Phenyl-substituted alkenoylguanidides, process for their preparation, their use as drugs or in diagnostic agents and drugs containing them
CA2009579A1 (en) Insulin analogs
IT8522574A0 (it) Composizione farmaceutica eprocedimento per trattare il corpo umano con essa.
IL96276A0 (en) Transdermal delivery system of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
IL94059A0 (en) Reconstituted blood cell compositions and processes for the preparation thereof
IE900580L (en) Therapeutic system for the retarded and controlled¹transdermal or transmucous administration of active¹substances (ii)
GB2314022B (en) Blending medical composition with sustained medicament releasability and process for preparing the same
NZ511020A (en) Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
IL115390A0 (en) Diffusion cell fro in vitro transcorneal drug penetration studies
GR3031354T3 (en) Soluble interferon -receptor, its preparation and use.
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
AU533524B2 (en) 6-substituted-11-alkylene morphanthridines
HU9603108D0 (en) Matrix system for the transdermal delivery of ibuprofen, and method for preparing same
AU623165B2 (en) Method of inhibiting the spread of disease and infection in structures
EP0263552A3 (en) Composite material for medical or paramedical, particularly orthopaedic use and method for manufacturing it
IL88608A0 (en) 3-hydroxy-2-(4-methoxyphenyl)-5-(2-methylaminoethyl)-2-3,dihydro-5h-1,5-benzothiazepin-4-one derivatives,their preparation and their application in therapy
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
IT8820871A0 (it) Composizione farmaceutica che si accumula nella pelle e procedimento per la sua preparazione.
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it
EP0897988A4 (en) TKR1785'S PHYSIOLOGICALLY ACTIVE SUBSTANCES, THEIR PROCESS AND MICROBE